Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Trial of Gadolinium Texaphyrin (PCI-0120) Injection as a Radiation Sensitizer in Patients Receiving Whole Brain Radiation Therapy for the Treatment of Brain Metastases

NCT00003563 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT00003563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Trial of Gadolinium Texaphyrin (PCI-0120) Injection as a Radiation Sensitizer in Patients Receiving Whole Brain Radiation Therapy for the Treatment of Brain Metastases
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 1998
Completion date
June 30, 2005
Enrollment
430 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic cancer